ACG Announces $200 Million Investment to Expand in the U.S.

ACG plans a $200 million investment in the U.S., with its first capsule manufacturing facility set to open in Atlanta, creating over 200 jobs by 2027

ACG, a leading global supplier of pharmaceutical and nutraceutical capsules, has announced a major $200 million investment in the United States, marking a significant step in its North American expansion strategy. The investment will be divided into two equal phases, with $100 million dedicated to building ACG’s first hard-shell capsule facility in Atlanta, Georgia, and another $100 million reserved for expanding its capacity and technological capabilities in the region.

According to ACG Group, the new facility will serve as a cornerstone for the company’s long-term growth in the North American market. The advanced manufacturing site will focus on producing empty hard-shell capsules, supporting both pharmaceutical and nutraceutical industries. Construction is already underway, and operations are expected to begin in early 2027.

The Atlanta plant will not only boost ACG’s local production but also create over 200 skilled jobs, reinforcing the company’s commitment to economic development and innovation in the U.S. manufacturing sector.

Strengthening North American Presence

ACG has been serving North American customers for over 25 years. The new facility represents a milestone in its commitment to bringing operations closer to its customers. The move is designed to enhance supply chain resilience, reduce lead times, and improve customer service through localized production and faster delivery cycles.

Karan Singh, Managing Director of ACG, highlighted the strategic importance of the investment:

“ACG has served North America for over 25 years. This facility strengthens our ties with customers across the region—bringing us closer to them, enabling faster lead times, higher-quality service, and a more resilient, de-risked supply chain. Just as importantly, it lets us respond more quickly and co-develop new innovations through tighter R&D partnerships. It’s been a long time coming, and we’re glad to say it’s here.”

Investing in Innovation and Sustainability

The new Atlanta facility will feature state-of-the-art capsule manufacturing technology, aligning with ACG’s commitment to quality, safety, and sustainability. By incorporating advanced automation, renewable energy integration, and efficient resource utilization, ACG aims to set new benchmarks in capsule production standards.

The second phase of investment, also worth $100 million, will be used to expand the company’s regional manufacturing capabilities, strengthen R&D collaboration, and introduce advanced material sciences into capsule design and production.

A Step Forward for the U.S. Pharma Manufacturing Ecosystem

ACG’s $200 million investment underscores the growing importance of the U.S. as a strategic hub for pharmaceutical manufacturing and innovation. As the company establishes its first production base in the country, it signals confidence in the U.S. market’s potential and positions ACG as a stronger partner for North American pharmaceutical and nutraceutical companies.

With this expansion, ACG not only reinforces its global leadership in capsule manufacturing but also contributes to building a more self-reliant and innovation-driven pharmaceutical ecosystem in the United States.